Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:10:07 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Q:SRPT - SAREPTA THERAPEUTICS INC - http://www.sareptatherapeutics.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SRPT - Q4.4114.55·149.874.5117.89+0.600.5546.163,9327,667117.00  119.08  115.9301159.89  55.25Apr 17Mar 2915 min RT 2¢

Recent Trades - Last 10 of 7667
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-29 16:00U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-04 08:30U:SRPTNews ReleaseSarepta Therapeutics to Present at Upcoming Investor Conferences
2024-02-29 18:16U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-29 09:00U:SRPTNews ReleaseSarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
2024-02-28 16:05U:SRPTNews ReleaseSarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
2024-02-21 08:30U:SRPTNews ReleaseSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
2024-02-16 07:00U:SRPTNews ReleaseSarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
2024-01-31 18:29U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-29 07:00U:SRPTNews ReleaseSarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
2024-01-16 09:02U:SRPTNews ReleaseSarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
2024-01-08 11:55U:SRPTNews ReleaseSarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
2024-01-02 08:30U:SRPTNews ReleaseSarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-29 18:27U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-22 08:00U:SRPTNews ReleaseSarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
2023-12-02 14:57U:SRPTNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
2023-11-18 18:00U:SRPTNews ReleaseROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
2023-11-02 08:30U:SRPTNews ReleaseSarepta Therapeutics to Present at the UBS Biopharma Conference
2023-11-01 16:05U:SRPTNews ReleaseSarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
2023-10-31 19:02U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-30 16:01U:SRPTNews ReleaseSarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy